Novartis joins Pfizer with FDA fast-track tag for lung cancer hopeful

Novartis joins Pfizer with FDA fast-track tag for lung cancer hopeful
Reuters: Health
Novartis has nabbed the U.S. Food and Drug Administration's breakthrough therapy designation for its experimental medicine capmatinib as it joins Pfizer in the race to treat a tough-to-treat mutated lung cancer type.